Immunostimulation using granulocyte- and granulocyte-macrophage colony stimulating factor in patients with severe sepsis and septic shock
Department of Nephrology and Intensive Care Medicine, University Medicine Berlin, Charité Campus Virchow Clinic, Augustenburger Platz 1, 13353 Berlin, Germany
Critical Care 2011, 15:136 doi:10.1186/cc10092
Please see related research by Bo et al, http://ccforum.com/content/15/1/R58Published: 31 March 2011
Sepsis is associated with failure of multiple organs, including failure of the immune system. The resulting 'sepsis-associated immunosuppression' resembles a state of immunological anergy that is characterized by repeated 'infectious hits', prolonged multiple-organ failure, and death. As a consequence, adjunctive treatment approaches using measures of immunostimulation with colony-stimulating factors (CSFs) were tested in animal experiments and clinical trials. Herein, data from randomized clinical trials will be discussed in the context of a recently published meta-analysis investigating the effects of granulocyte- and granulocyte-macrophage colony-stimulating factor therapy in patients with severe sepsis and septic shock.